Search clinical trials for: Multi-vessel Disease, Culprit Vessel Only

Total 14 results

Samsung Medical Center

Recruiting

Revascularization Strategy of Multivessel Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator (RESCUE-SHOCK)

Extracorporeal Membrane Oxygenation | Acute Myocardial Infarction | Cardiogenic Shock | Multi Vessel Coronary Artery Disease

Korea, Republic of
David Kong, M.D.
Medtronic Vascular; Terumo Medical Corporation; Volcano Corporation

Terminated

Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)

Myocardial Infarction

United States
Beijing Luhe Hospital

Completed

ECG-guided Immediate Primary PCI for Culprit Vessel to Reduce Door to Device Time

Myocardial Infarction

China
Dartmouth-Hitchcock Medical Center

Terminated

Treatment Decisions for Multi-vessel CAD

Coronary Artery Disease

United States
LeMaitre Vascular

Active, not recruiting

Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair

Vascular Diseases

China
Augusta University

Recruiting

Endovascular Embolization for Chronic Subdural Hematomas Following Surgical Evacuation (endovascular)

Chronic SDH and the Efficacy of Embolization

United States
Centre Hospitalier Universitaire, Amiens

Withdrawn

Interest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis (VOPRABIO)

Aortic Stenosis | Pulse Wave

France
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

HIV-1 Infection

United States
Boston Scientific Corporation
Cardialysis BV

Unknown

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries (SYNTAX)

Coronary Artery Disease

United States, Italy, Latvia, Netherlands, United Kingdom, France, Spain, Sweden, Germany, Hungary, Poland, Portugal, Austria, Belgium, Norway, Czech Republic, Denmark, Finland
Bayer

Completed

Data on Oral Contraceptives Compliance in Non Stop Regimen (DOC Non Stop)

Contraception

Poland
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University College, London
The Leeds Teaching Hospitals NHS Trust; Cambridge University Hospitals NHS... and other collaborators

Unknown

Ketogenic Diet in Infants With Epilepsy (KIWE) (KIWE)

Epilepsy

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States

Search clinical trials for: Multi-vessel Disease, Culprit Vessel Only

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations